Literature DB >> 8808100

Endocrine ophthalmopathy in a patient under continuous immunosuppressive therapy after cardiac transplantation.

G Höfle1, R Moncayo, I Baldissera, R Pfister, G Finkenstedt.   

Abstract

We present the case of a female patient who has been on immunosuppressive therapy consisting of cyclosporin A and prednisolone for 9 years because of heterotopic (auxiliary) heart transplantation in 1984. In 1992 the patient developed Graves' disease followed by endocrine ophthalmopathy class IV 1 year later. To our knowledge this is the first report on Graves' disease with subsequent severe endocrine ophthalmopathy in a patient under immunosuppressive treatment with cyclosporin A and prednisolone in doses that effectively prevent heart transplant rejection. Prednisolone, which is used as a first line treatment of endocrine ophthalmopathy, and cyclosporin A, both inhibit T cell function. However, in this patient they were not effective in preventing the development of Graves' disease with subsequent endocrine ophthalmopathy, both of which are autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8808100     DOI: 10.1089/thy.1995.5.477

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  3 in total

1.  Graves' hyperthyroidism and ophthalmopathy associated with pemphigus vulgaris: onset of thyroid autoimmune disease during chronic low-dose glucocorticoid therapy.

Authors:  L Bartalena; F Bogazzi; L Chiovato; M L Tanda; E Martino
Journal:  J Endocrinol Invest       Date:  1997-03       Impact factor: 4.256

2.  Development of Graves' disease in a patient under immunosuppressive therapy after liver transplantation.

Authors:  T Bednarczuk; U Makowska; J Nauman
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

3.  Onset of Graves' disease during long-term immunosuppressive therapy in a patient with membranous nephropathy.

Authors:  Hiroaki Iwasaki
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2015-08-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.